Clinical Trial

Autophagy Maintenance (AUTOMAIN)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-06; most recent amendment 2025-12-18.
Status change: Not Yet Recruiting → Recruiting 2025-12-18
Trial Details
NCT Number NCT06971744
Lead Sponsor Medical University of South Carolina
Conditions Ovarian Cancer
Enrollment 38 participants
Start Date 2025-12-18
Primary Completion 2028-06-18 (estimated)
Study Completion 2029-06-18 (estimated)
Updated on ClinicalTrials.gov 2025-12-22